We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT03883412

Type 2 diabetes · Phase 4 · Recruiting now

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

NCT03883412 · Sponsor: University of Virginia

What this trial means for you

This study is recruiting now at 1 US site. It's studying Liraglutide for type2 diabetes.

Who can joinAll sexes, 21 Years – 60 Years
Healthy volunteersAccepted
What you'd takeLiraglutide
Study length~8.3 years overall
Planned participants60
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Age 21-60 * A1C ≤ 8.5% * Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton) * On stable dose of oral hypoglycemic agents \>4 months * On stable dose of other medications for \>4 months Exclusion Criteria: * Taking Insulin * Smoking presently or in the past 6 months * BP \>160/90 * BMI \>35 * Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome * History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease. * Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease * Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI). * Pregnant or breastfeeding. * Known hypersensitivity to perflutren (contained in Definity)

Study sites by state

Virginia

  • University of Virginia, Charlottesville · Recruiting now

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth